EYPTJPMPresentationJanuary2025vF2

J.P. Morgan Healthcare Conference PresentationJanuary 14, 2025Jay Duker, M.D.President and CEO©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.Legal Disclaimers©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.2Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statementsthat address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements , including but not limited to statements regarding: our expectations regarding the timing and clinical development of DURAVYUin Wet AMD and DME, our expectations regarding the enrollment, dosing and data readouts for the LUGANO trial and the LUCIA trial; our optimism that that DURAVYU has the potential to change the current treatment paradigm and revolutionize real-world out